echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Nutrition News > Kang Cai | ChromaDex sells 25 million US dollars of common stock Xianle Health to issue convertible bonds application approved

    Kang Cai | ChromaDex sells 25 million US dollars of common stock Xianle Health to issue convertible bonds application approved

    • Last Update: 2021-03-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Original title: Kang Cai | ChromaDex sells US$25 million common shares of Xianle Health to issue convertible bonds application approved

    ChromaDex announces the sale of $25 million in common stock

    ChromaDex announces the sale of $25 million in common stock

    On February 22, ChromaDex (NASDAQ:CDXC) announced that it would sell its common stock of US$25 million in a private placement, led by a new international investor.


    On February 22, ChromaDex (NASDAQ:CDXC) announced that it would sell its common stock of US$25 million in a private placement, led by a new international investor.


    Rob Fried ChromaDex CEO, said: "With this additional funding, we intend to expand by nicotinamide riboside (NR) and other scientific NAD + precursor to further strengthen our leading position as the world's NAD +.


    Xianle Health's application for issuance of convertible bonds was approved

    On February 24, Xianle Health announced that the Shenzhen Stock Exchange’s Growth Enterprise Market Listing Committee reviewed the company’s application for the issuance of convertible corporate bonds to unspecified targets.


    On February 24, Xianle Health announced that the Shenzhen Stock Exchange’s Growth Enterprise Market Listing Committee reviewed the company’s application for the issuance of convertible corporate bonds to unspecified targets.


    "Scientific Research Report on Dietary Guidelines for Chinese Residents (2021)" released

    On February 25, the "Scientific Research Report on Dietary Guidelines for Chinese Residents (2021)" compiled by the Chinese Nutrition Society was officially released.


    On February 25, the "Scientific Research Report on Dietary Guidelines for Chinese Residents (2021)" compiled by the Chinese Nutrition Society was officially released.


    The "Report" pointed out that over the 70 years since the founding of New China, my country’s nutritional security and supply capabilities have been significantly enhanced, the health of the people has continued to improve, and the average life expectancy has increased from 35 to 77.
    3 years.
    The problems of undernutrition and physical development of residents have continued to improve.
    This is reflected in the adequate dietary energy and macronutrient intake of residents, the continuous increase in high-quality protein intake, the continuous increase in average height of residents, and the significant reduction in growth retardation rate of children under 5 in rural areas.
    These are the main contributions to adequate food supply and improved dietary quality.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.